eMIMS New Product
Thalidomide available in the UK
28-Aug-08
Thalidomide Pharmion has been granted a licence for use in combination with melphalan and prednisolone as first-line treatment for patients with untreated multiple myeloma aged 65 years or over, or patients who are not eligible for high-dose chemotherapy.
Originally developed as treatment for insomnia and morning sickness in the 1950s, thalidomide has since been shown to be highly active against myeloma. It has immunosuppressive properties that appear to inhibit the growth and survival of myeloma cells, as well as inhibit the growth of new blood vessels.
To prevent exposure of pregnant women to thalidomide, healthcare professionals and patients are required to adhere to the measures specified in the Thalidomide Pharmion Pregnancy Prevention Programme. The programme links product supply to education of the prescriber, dispensing pharmacist and patient.
View Thalidomide Pharmion drug record
Further information: Celgene Ltd
Quick search - use * for an abbreviated search, eg nico*
Tools
Related Articles
Related Guidelines
Related Fact Sheets
Related Drugs By Area
Latest Guidelines
- Osteoporotic Fragility Fractures in Postmenopausal Women: Primary Prevention (NICE)
- Osteoporotic Fragility Fractures in Postmenopausal Women: Secondary Prevention (NICE)
- VTE, Prevention of: Dabigatran (NICE)
- Influenza Prophylaxis: Oseltamivir, Amantadine and Zanamivir (NICE)
- Hepatitis B, Chronic: Entecavir (NICE)
GMS Contract Action Plan
Jobs
Job of the Week
- Practice Manager South East England
- Practice Manager North West England
- GP assistant East of England
Comments
Snail
02/09/2008
Why is this drug so expensive now? Approximately £300 for 28 capsules - it surely didn't cost this much when released in the 1950s for treatment of insomnia?
Only registered users may comment. Log in now or register for a free account.